



PATENT
Customer No. 22,852
Attorney Docket No. 09095.0005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
LINK et al.)	Group Art Unit: 1624
)	
Application No.: 09/541,795)	Examiner: S. Patel
)	
Filed: March 31, 2000)	
)	
For: CELL ADHESION-INHIBITING)	Mail Stop AF
ANTIINFLAMMATORY AND)	
IMMUNE-SUPPRESSIVE)	
COMPOUNDS)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Assignee, Abbott Laboratories, duly organized under the laws of Illinois and having its principal place of business at 100 Abbott Park Road, Abbott Park, IL, 60064-6050, represents that it is the assignee of the entire right, title and interest in and to the above-identified application, Application No. 09/541,795, filed March 31, 2000, for CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS in the names of LINK et al., as indicated by the assignment duly recorded in the United States Patent and Trademark Office at Reel 010819, Frame 0290 on May 15, 2000. Assignee, Abbott Laboratories, further represents that it is the assignee of the entire right, title and interest in and to U.S. Patent Application No.

10/356,794 (reissue of U.S. Patent No. 6,110,922), as indicated by the assignment duly recorded in the United States Patent and Trademark Office at Reel 009750, Frame 0676 on February 8, 1999.

To obviate a provisional double patenting rejection, assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of any patent granted on co-pending application No. 10/356,794. Assignee hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on co-pending application No. 10/356,794 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Assignee does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of any patent granted on co-pending application No. 10/356,794, as presently shortened by any terminal disclaimer, in the event that any patent granted on co-pending application No. 10/356,794 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

In accordance with the fee schedule set forth in 37 C.F.R. § 1.20(d), the required fee of \$110.00 is being filed with this disclaimer.

If a check for the required fee is not filed concurrently herewith or if there are any additional fees due in connection with the filing of this Terminal Disclaimer, please charge the fees to Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to Deposit Account No. 06-0916

The undersigned is an attorney of record.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: May 25, 2004

By: *Maria T. Bautista*
Maria T. Bautista
Reg. No. 52,516